Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Existing two-drug combinations for aging, pain, and inflammation in knee osteoarthritis
NL-OMON61172Phase 2Withdrawn
- Sponsor
- Radboud University Medical Center
- Start
- Jun 2026
- Modality
- Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of metformin, baricitinib, dolutegravir, colchicine in osteoarthritis (OA), sponsored by Radboud University Medical Center. Planned start Jun 2026; status: withdrawn.
02
Drugs
metforminbaricitinibdolutegravircolchicine
03
Conditions
osteoarthritis (OA)
Beyond the preview
Go deeper on NL-OMON61172.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61172.